SWOT analysis for the MENA region

STRENGTHS WEAKNESSES

S  Commitment to healthcare remains a priority

for most MENA governments, accelerating
 Regulatory issues perpetuate a high-risk
market for innovative drugmakers
W
the modernization and expansion of  The majority of markets are highly import-
healthcare infrastructure and provision reliant owing to weaknesses in the
 The region’s high burden of chronic domestic drug manufacturing industry
diseases, particularly cancer, diabetes and
cardiovascular disease, will continue to
stimulate interest in generic and innovative
drugmakers.

OPPORTUNITIES THREATS

O  Preventative measures will be increasingly

leveraged on in the region, presenting a key
 Rapidly growing youth population threaten
long-term opportttunities for
T
opportunity for multinational pharmaceutical pharmaceutical firms in MENA.
firms to partner with authorities on disease  Local and regional political instatbilities will
awareness programs as they adapt to the continue to discourage foreign drugmaker
potential shift in patient movement investment.
 Economic growth in the GCC will bring
infrastructure growth and influence spending
patterns in key markets as a knock-on effect
of rising oil prices and crude output growth
 Rapid population growth across the MENA
region indicates greater long term demand
for medicines and will be seen as a positive
for drugmakers

Sunday, November 29, 2020 Pricing and Market Landscape in MENA Page 1